Crossmark

Role of brentuximab vedotin plus sirolimus in the treatment of classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder: a case-based review

Crossref DOI link: https://doi.org/10.1007/s00277-023-05446-5

Published Online: 2023-09-26

Published Print: 2024-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhou, Kuangguo

Gong, Duanhao

Han, Yunfeng

Huang, Wei https://orcid.org/0000-0001-6959-7077
License Information

Text and Data Mining valid from 2023-09-26

Version of Record valid from 2023-09-26
More Information

Article History

Received: 1 April 2023

Accepted: 6 September 2023

First Online: 26 September 2023

Declarations

:

: The studies involving human participants were reviewed and approved by the Ethical Review Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.

: Written informed consent has been obtained from the patient to publish this paper.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below